SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

FORM 8-K

__________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): ~~February~~January 218, ~~2021~~2022

CANNAGISTICS, INC.

(Exact name of registrant as specified in charter)

Delaware

000-55711

86-3911779

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

150 Motor Parkway, Suite 401

Hauppauge, NY

11788

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: 631-787-8455

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange. [ ]

Item 51.0201 ~~Departure~~Entry ofinto ~~Directors~~a orMaterial ~~Certain~~Definitive ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Agreement

On January 18, 2022, the Company, through its subsidiary, The Integrity Wellness Group, Inc., (b“Integrity Wellness”) entered into a Joint Venture/Partnership Agreement (“Agreement”) with Medizone Bio, Inc., (“Medizone Bio”) of Richmond Hill, Ontario, Canada. The Agreement provides for a 50/50 partnership for the production of biodegradable face masks, and medical supplies, such as personal protective equipment (cPPE) and COVID-19 testing materials. Under the Agreement, Integrity Wellness is to provide an initial funding of $300,000 in financing for Medizone Bio to manufacture the first Medizone Bio products purchase order. This purchase order has a value of $1,200,000. The Company has borrowed the money for this purpose as described below.

OnIntegrity ~~December~~Wellness 6,will ~~2021~~provide the partnership with financing, ~~Cannagistics~~marketing, ~~Inc.~~sales ~~(the~~distribution ~~“Company”)~~in wholesale, ~~finalized~~retail ~~the~~and ~~appointment~~direct-to-consumer of(e,g., QVC, ~~Jim~~HSN, ~~Morrison~~Amazon, 62etc.), asfinancing ~~the~~for ~~Company’s Chief~~general ~~Executive~~working ~~Officer~~capital and ~~President~~purchase order financing, ~~effective~~while ~~immediately~~Medizone ~~upon~~Bio provides the ~~resignatikon~~partnership with ofa ~~employment~~series of ~~Rob~~purchase ~~Gietl,~~orders. ~~the~~The ~~then~~net ~~Chief~~profits, ~~Executive Officer.~~if ~~Mr.~~any, ~~Morrison~~will ~~was~~be ~~appointed~~distributed tobetween the ~~Company’s~~partners ~~Board of Directors~~ in ~~November~~equal ~~2021~~proportions.

~~Mr.~~Integrity ~~Morrison’s~~Wellness ~~biographical~~has ~~information~~issued asa ~~required~~Promissory byNote ~~Item 401(b)~~ in the principal amount of ~~Regulation~~ ~~S-K~~$300,000 ~~and~~to ~~business~~7X ~~experience~~Enterprises, asInc. ~~required by Item 401~~(e“7X”) ~~of Regulation~~ ~~S-K was~~in ~~previously~~exchange ~~disclosed~~for 7X inadvancing $300,000 to Integrity Wellness for the ~~Company’s~~purchase ~~Current~~order ~~Report~~financing onfor ~~Form~~the ~~8-K~~initial ~~filed~~purchase order of Medizone Bio. The Promissory onNote ~~November~~bears interest at a rate of 10,% ~~2021~~per annum and is due upon demand from the holder.

InItem ~~connection with the appointment of Mr~~9.01 Financial ~~Morrison,~~Statements ~~effective December 6, 2021, Rob Gietl resigned as President, Chief Executive Officer~~ and ~~director of the Company.~~Exhibits

~~Item~~(d) 8Exhibits.~~01 Other Events.~~

On February 2, 2021, the Supreme Court of the State of New York, County of Suffolk entered an order granting summary judgment to Jeffrey Gates, the plaintiff, against Cannagistics, Inc., a Nevada corporation, which is a subsidiary of the Company, and James Zimbler, our Vice President of Operations and former director, the defendants (Index No. 602019/2020), for $151,712.

Exhibit No.		Exhibit

10.1		Partnership Agreement between The Integrity Wellness Group, Inc. and Medizone Bio, Inc.
10.2		Promissory Note between The Integrity Wellness Group, Inc., and 7X Enterprises, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cannagistics, Inc.

Date: December 16, 2021

/s/ James W. Zimbler

Date: January 25, 2022

/s/ Jim Morrison

James W. Zimbler Vice President

Jim Morrison, President

Filing Compare · Cannagistics Inc.